The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• patients with pancreatic cancer who had undergone curative-intent surgery (R0 or R1 resection);
• both sexes, age ≥18 years old;
• ECOG performance status score ≤2;
• the expected survival time was ≥3 months.
Locations
Other Locations
China
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING
Beijing
Contact Information
Primary
Chunmei Bai, MD
tangh160706@163.com
010-69158764
Time Frame
Start Date: 2023-02-01
Estimated Completion Date: 2030-02-01
Participants
Target number of participants: 100
Treatments
Experimental: MRD-guided
Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will receive a later-line therapy.
No_intervention: Routine treatment
Patients with elevated MRD from baseline at the first imaging assessment but without radiographic progressive disease will continued their current therapy.
Related Therapeutic Areas
Sponsors
Leads: Peking Union Medical College Hospital